Penpulimab injection
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., The First Affiliated Hospital with Nanjing Medical University, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Conditions
Advanced Hepatocellular CarcinomaAdvanced Pancreatic CancerCarcinomaColorectal CancerDigestive System DiseasesGastric CancerGastroesophageal-junction CancerGastrointestinal Diseases
Phase 1
To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma
NCT05400876
Start: 2022-06-09End: 2023-10-31Target: 92Updated: 2023-02-14
A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).
TerminatedNCT05975645
Start: 2023-08-15End: 2025-06-04Updated: 2025-08-12
A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.
NCT06010901
Start: 2024-01-13End: 2025-07-31Target: 75Updated: 2024-01-23
Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.
TerminatedNCT06320080
Start: 2024-05-30End: 2025-11-03Updated: 2025-11-21
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
RecruitingNCT06821503
Start: 2025-04-11End: 2028-12-01Target: 72Updated: 2026-03-10
Phase 2
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
RecruitingNCT05494060
Start: 2022-03-16End: 2027-02-28Target: 80Updated: 2023-11-07
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
RecruitingNCT06081673
Start: 2023-10-30End: 2026-10-30Target: 72Updated: 2023-10-13